2008Expert Opinion on Drug Metabolism & ToxicologyRequires access

Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis

Barry A. Schechter

Open publisher page 16 citations

Abstract

BACKGROUND: Acular LS (ketorolac tromethamine 0.4%) ophthalmic solution, a reformulation of the original Acular (ketorolac tromethamine 0.5%), is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. OBJECTIVE: This manuscript will review the off-label application of this topical NSAID medication as a treatment for allergic conjunctivitis. METHODS: An extensive MedLine search was undertaken to evaluate data on the use of ketorolac for allergic conjunctivitis. Data on both human and animal data were reviewed. RESULTS/CONCLUSIONS: Studies have demonstrated that ketorolac 0.4% has equivalent efficacy to ketorolac 0.5%. Several studies have demonstrated that ketorolac effectively treats allergic conjunctivitis. Ketorolac 0.4% is effective when used as either monotherapy or as adjunct therapy to steroids.

About this research paper

What this paper is about

BACKGROUND: Acular LS (ketorolac tromethamine 0.4%) ophthalmic solution, a reformulation of the original Acular (ketorolac tromethamine 0.5%), is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. OBJECTIVE: This manuscript will review the off-label application of this topical NSAID medication as a treatment for allergic conjunctivitis. METHODS: An extensive MedLine search was undertaken to evaluate data on the use of ketorolac for allergic conjunctivitis. Data on both human and animal data were reviewed. RESULTS/CONCLUSIONS: Studies have demonstrated that ketorolac 0.4% has equivalent efficacy to ketorolac 0.5%. Several studies have demonstrated that ketorolac effectively treats allergic conjunctivitis. Ketorolac 0.4% is effective when used as either monotherapy or as adjunct therapy to steroids.

Why it matters

OpenAlex reports 16 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: Acular LS (ketorolac tromethamine 0.4%) ophthalmic solution, a reformulation of the original Acular (ketorolac tromethamine 0.5%), is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. OBJECTIVE: This manuscript will review the off-label application of this topical NSAID medication as a treatment for allergic conjunctivitis. METHODS: An extensive MedLine search was undertaken to evaluate data on the use of ketorolac for allergic conjunctivitis. Data on both human and animal data were reviewed. RESULTS/CONCLUSIONS: Studies have demonstrated that ketorolac 0.4% has equivalent efficacy to ketorolac 0.5%. Several studies have demonstrated that ketorolac effectively treats allergic conjunctivitis. Ketorolac 0.4% is effective when used as either monotherapy or as adjunct therapy to steroids.

Key concepts: Ketorolac Tromethamine, Ketorolac, Medicine, Dermatology, Pharmacology, Anesthesia, Analgesic

Related papers

Back to paper searchBrowse research topicsOriginal source
Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis — Research Paper | ScholarLens